Novel Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.20 M
- Company Age 30 Year, 8 Months
- Open Charges ₹ 8.77 Cr
About Novel Drugs
Novel Drugs Limited (NDL) is a Public Limited Indian Non-Government Company incorporated in India on 03 June 1994 and has a history of 30 years and eight months. Its registered office is in Mylapore, Chennai.600 004, Tamil Nadu.
The Company is engaged in the Pharma Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹8.77 Cr.
Gnanatilakan Sebastian, Chandra Gnanatilakan, Karunakaran Sebastin, and One other member serve as directors at the Company.
Company Details
-
LocationMylapore, Chennai.600 004, Tamil Nadu
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231TN1994PLC027710
-
Company No.
027710
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
03 Jun 1994
-
Date of AGM
-
-
Date of Balance Sheet
-
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Novel Drugs?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gnanatilakan Sebastian
|
Director | 30-Jul-1996 | Current |
|
Chandra Gnanatilakan
|
Director | 14-Aug-2008 | Current |
|
Karunakaran Sebastin
|
Director | 03-Jun-1994 | Current |
|
Mary Justine
|
Director | 14-Aug-2008 | Current |
Financial Performance of Novel Drugs.
Enhance accessibility to Novel Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novel Drugs?
Unlock access to Novel Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Medzone Pharmaceuticals Private LimitedChandra Gnanatilakan is a mutual person
Charges (Loans)
₹8.77 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 8.00 Cr
- The Lakshmi Vilas Bank Ltd. : 0.77 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Mar 2005 | State Bank Of India | ₹3.48 Cr | Open |
| 27 Jan 2005 | State Bank Of India | ₹2.41 Cr | Open |
| 18 Dec 2003 | State Bank Of India | ₹1.96 Cr | Open |
| 31 Mar 2000 | The Lakshmi Vilas Bank Ltd. | ₹7.70 M | Open |
| 23 Sep 1996 | State Bank Of India | ₹1.48 M | Open |
How Many Employees Work at Novel Drugs?
Unlock and access historical data on people associated with Novel Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novel Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novel Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
